Meeting
2023 ASCO Annual Meeting
A phase 0 pharmacokinetic trigger trial of infigratinib in patients with recurrent high-grade glioma.
Authors
Nader Sanai
Ivy Brain Tumor Center, Phoenix, AZ
Nader Sanai , Tigran Margaryan , Jennifer Molloy , Anita DeSantis , Jocelyn Harmon , Amy Hong , Kelly Braun , John Wanebo , Wonsuk Yoo , An-Chi Tien , Artak Tovmasyan , Shwetal Mehta
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Central Nervous System Tumors
Track
Central Nervous System Tumors
Sub Track
Primary CNS Tumors–Glioma
Clinical Trial Registration Number
NCT04424966
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 2051)
DOI
10.1200/JCO.2023.41.16_suppl.2051
Abstract #
2051
Poster Bd #
408
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
An exploratory clinical trial on intra-lumbar injection of B7H3-specific allogeneic universal CAR-T cells in patients with recurrent high-grade gliomas.
First Author: Xiaoyun Shang
Poster
2023 ASCO Annual Meeting
A phase 0/2 trigger trial of niraparib in patients with newly diagnosed glioblastoma.
First Author: Shwetal Mehta
Poster
2017 ASCO Annual Meeting
A phase I study to assess the safety, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activities of daily oral BAL101553, a novel tumor checkpoint controller (TCC) in adult patients with progressive or recurrent glioblastoma (GBM) or high-grade glioma.
First Author: Alvaro Henrique Ingles Garces
Poster
2016 ASCO Annual Meeting
Phase I/II study of S49076, a multi-target inhibitor of c-MET, AXL, FGFR in combination with bevacizumab in patients with recurrent glioblastoma.
First Author: Khe Hoang-Xuan